Therapeutic Efficacy of Oral Tofacitinib in Pediatric Prurigo Nodularis: A Case Series With a Review of Literature

Abstract

Keywords

pediatric prurigo nodularis oral tofacitinib JAK inhibitors tofacitinib prurigo

Get full access to this article

View all access options for this article.

References

Huang

Roh

Sutaria

, et al. Real-world disease burden and comorbidities of pediatric prurigo nodularis. J Am Acad Dermatol. 2022;86:655-657. doi:10.1016/j.jaad.2021.02.030

Yiling

Ali

Jiayang

, et al. Effectiveness of dupilumab in pediatric patients with prurigo nodularis-like atopic dermatitis. Dermatitis. 2023;34(2):162-163. doi:10.1089/derm.2022.29008.yyi

Kyvayko

Fachler-Sharp

Greenberger

Horev

Molho-Pessach

Characterisation of paediatric prurigo nodularis: a multicentre retrospective, observational study. Acta Derm Venereol. 2024;104:adv15771. doi:10.2340/actadv.v104.15771

Gowda

Ameta

Garg

Behera

Successful use of tofacitinib in paediatric prurigo nodularis: a report of four cases. Indian J Dermatol. 2025;70(2):102-104. doi:10.4103/ijd.ijd_842_24

Yew

Yeo

PM.

Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore. JAAD Int. 2023;13:13-14. doi:10.1016/j.jdin.2023.06.005